Form 4: Tenon Medical CFO Kevin Williamson Granted RSUs

Tenon Medical's Chief Financial Officer and Director, Kevin Williamson, was granted 117,974 restricted stock units, vesting in two tranches in 2026.

Summary

• Kevin Williamson, who serves as both a Director and Chief Financial Officer of Tenon Medical, Inc. (TNON), was granted 117,974 Restricted Stock Units (RSUs).
• The transaction date for this grant was October 13, 2025.
• Each restricted stock unit represents a contingent right to receive one share of Tenon Medical common stock.
• Fifty percent (50%) of the granted RSUs will vest and automatically convert into common stock on January 1, 2026.
• The remaining fifty percent (50%) of the RSUs will vest and automatically convert into common stock on July 31, 2026.
• Following this reported transaction, Kevin Williamson beneficially owns 117,974 derivative securities (RSUs) directly.

Sentiment

Score: 6

Explanation: The grant of restricted stock units to a key executive is generally a neutral to slightly positive event, as it aligns management's interests with shareholders through equity compensation, without representing a direct cash investment by the executive or a significant change in company operations.

Positives

• The grant of Restricted Stock Units to a key executive like the CFO and Director aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• This form of equity compensation is a standard practice to incentivize and retain executive talent.

Future Outlook

The future outlook indicates that Kevin Williamson will acquire 117,974 shares of Tenon Medical common stock upon the vesting of his Restricted Stock Units, with half converting on January 1, 2026, and the other half on July 31, 2026.

Industry Context

The grant of restricted stock units to a Chief Financial Officer and Director is a common executive compensation practice across various industries, designed to align executive incentives with long-term shareholder value creation. This type of compensation is prevalent in publicly traded companies, particularly in the medical device or healthcare sector where Tenon Medical operates, to attract and retain experienced leadership.

Stakeholder Impact

• Shareholders: The grant of RSUs to the CFO and Director enhances alignment between executive compensation and shareholder interests, as the value of the RSUs is tied to the company's stock performance.
• Employees: This action reflects standard executive compensation practices, which can positively influence overall employee morale and retention strategies by demonstrating commitment to key personnel.

Next Steps

• Vesting of 50% of the Restricted Stock Units on January 1, 2026.
• Vesting of the remaining 50% of the Restricted Stock Units on July 31, 2026.

Key Dates

Keywords

Tenon Medical, TNON, Kevin Williamson, Restricted Stock Units, RSU, Insider Transaction, Executive Compensation, Form 4, CFO, Director